Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
ESMO Congress 2025
ACS Clinical Congress 2025
2025 ASCO Quality Care Symposium
2025 ASTRO Annual Meeting
2025 Debates and Didactics in Hematology and Oncology
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
2015 New Orleans Summer Cancer Meeting,2015 New Orleans Summer Cancer Meeting
«
1
»
Advertisement
Advertisement
Oct
31
Today In Oncology
Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Atezolizumab, Venetoclax, and Obinutuzumab in Richter Transformation Diffuse Large B-Cell Lymphoma
Glofitamab or Rituximab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory DLBCL
Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL
FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory LBCL
View More
Advertisement
